A drug that has been used to slow progression of kidney and cardiovascular disease in people with type 2 diabetes may also help people with chronic kidney disease who do not have diabetes, according ...
Hypertension affects 1 in 3 adults globally and is the leading modifiable risk factor for cardiovascular disease. Aldosterone dysregulation, often driven by obesity and primary aldosteronism, affects ...
Unprecedented access to a unique group of Australians is allowing researchers to study links between raised aldosterone levels and elevated cardiovascular risk in various age groups—with important ...
Persistent hyponatremia despite treatment prompts further evaluation, revealing isolated aldosterone deficiency despite normal adrenal function and leading to effective therapy.
Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in ...
A potential association between the use of angiotensin-receptor blockers (ARBs) and angiotensin-converting–enzyme (ACE) inhibitors and the risk of coronavirus disease 2019 (Covid-19) has not been well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results